WASHINGTON (Reuters)—U.S. Food and Drug Administration (FDA) Chief Scott Gottlieb said he plans to step down in a month, calling into question how the agency will handle critical issues, such as e-cigarette use among teens and efforts to increase competition in prescription drugs.
The U.S. Department of Health and Human Services (HHS), which oversees the FDA, announced Mr. Gottlieb’s resignation on Tuesday, March 5.
Mr. Gottlieb was well regarded and won bipartisan support for his efforts to curb the use of flavored e-cigarettes by youths, speed approval times for cheap generic medicines to increase competition and bring down prescription drug prices and boost the use of cheaper versions of expensive biotech medicines, called biosimilars.
“Scott’s leadership inspired historic results from the FDA team, which delivered record approvals of both innovative treatments and affordable generic drugs, while advancing important policies to confront opioid addiction, tobacco and youth e-cigarette use,” HHS Secretary Alex Azar said in a statement.